Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

European Journal of Cancer

Unlocking clinical quantum oncology through quantum control

Bruno F. E. Matarèse, Arnie D. Purushotham

Published Jul 15, 2025• 10 citations
Publisher
DOI
10.1016/j.ejca.2025.115632

Related papers

Quantum computing for oncology

Siddhi Ramesh, Teague Tomesh, Samantha J. Riesenfeld +2 more

Nature Cancer•May 17, 2024•20 citations

Quantum Oncology: The Applications of Quantum Computing in Cancer Research

Jiaran Li, Li Li, Ning Liu +3 more

Journal of Medical Systems•Jul 23, 2025•8 citations

Quantum Oncology

Bruno F. E. Matarèse, Arnie D. Purushotham

Quantum core technologies (computing, sensing, imaging, communication) hold immense promise for revolutionizing cancer care. This paper explores their distinct capabilities in early-stage cancer diagnosis, improved clinical workflows, drug discovery, and personalized treatment. By overcoming challenges such as infrastructure and ethical considerations, these processes can unlock faster diagnoses, optimize therapies, and enhance patient outcomes.

Quantum Reports•Feb 18, 2025•21 citations

The Rise of Generalist Foundation Models and Quantum Computing in Oncology

Manish Kakar

In the field of oncology, Artificial intelligence (AI) and deep learning (DL) are an essential component of decision-support. However, traditional narrow-AI models have significant limitations in clinics with respect to narrow, task-specificity (TS), high data requirement and interpretability. Moreover, the absence of common clinical criteria and the lack of doctors in the co-development of explainable AI (XAI) have undermined the implementation causing conflict with general data protection regulation (GDPR), trust and ethical integration requirements. The application of AI/DL tools in clinics are often constrained by TS, heavy dependency on hyperparameter tuning and large data volume. This review fills in these gaps by creating a cohesive framework that links problem-driven clinical demands with emerging technologies, specifically, the convergence of Generalist Medical AI (GMAI) and Quantum Oncology (QO). Although GMAI's use foundation models, have high computational requirements and have inherent complexity in their validation pipelines, they are designed to be based on self-supervised learning from multimodal data to address a range of downstream clinical tasks. This review aims to critically discuss the potential of quantum computing (QC) to augment GMAI for more efficient data processing, medical imaging, drug discovery, and genomic analysis, owing to the inherent strengths of quantum superposition and entanglement that surpass the capabilities of classical AI/DL systems. Structural and technical trade-offs of this paradigm change are also discussed. We also give recommendations for safe bedside translation by facilitating a common assessment through clinician in the loop design, the CLAIM checklist, and the framework FUTURE-AI. Finally, this analysis outlines oncology and quantum convergence into quantum oncology (QO). This enables scalable, sustainable, and precision oncology while respecting ethics and privacy.

Technology in Cancer Research & Treatment•Aug 1, 2026•0 citations

Quantum Machine Learning in Oncology: A Systematic Review of Clinical Applications, Challenges, and Future Research Directions

Khairil Imran Ghauth, Yanche Ari Kustiawan

Quantum machine learning (QML) has emerged as a promising approach for analyzing the complex, high-dimensional data encountered in oncology, yet research in this area remains fragmented. This systematic literature review synthesizes current applications of QML in cancer care. Following PRISMA guidelines, six databases were searched for peer-reviewed English-language studies published between 2020 and 2026. Of the 212 records identified, 49 studies met the inclusion criteria after screening and quality assessment. The findings show that QML research is dominated by classification and detection tasks, while segmentation is beginning to emerge. Breast cancer and brain tumors are the most frequently investigated domains. Hybrid quantum-classical models, particularly quantum kernel methods, quantum neural networks, and quantum convolutional neural networks, are the predominant approaches. The main barriers to adoption are hardware limitations, including quantum noise, limited qubit availability, and reliance on simulators. Overall, QML in oncology remains in its early stages of development, with limited clinical validation, insufficient model interpretability, and little evidence of a clear quantum advantage. Future research should prioritize evaluation on real quantum hardware, larger and more diverse clinical datasets, standardized benchmarking against classical methods, and closer collaboration between computer scientists and oncology experts to facilitate clinical translation.

Machine Learning and Knowledge Extraction•Aug 13, 2026•1 citation

The future of quantum computing in healthcare

R. M. Tharsanee, B. Vishnuupriya, C. Anand Deva Durai

Elsevier eBooks•Jan 1, 2025•2 citations
In the field of oncology, Artificial intelligence (AI) and deep learning (DL) are an essential component of decision-support. However, traditional narrow-AI models have significant limitations in clinics with respect to narrow, task-specificity (TS), high data requirement and interpretability. Moreover, the absence of common clinical criteria and the lack of doctors in the co-development of explainable AI (XAI) have undermined the implementation causing conflict with general data protection regulation (GDPR), trust and ethical integration requirements. The application of AI/DL tools in clinics are often constrained by TS, heavy dependency on hyperparameter tuning and large data volume. This review fills in these gaps by creating a cohesive framework that links problem-driven clinical demands with emerging technologies, specifically, the convergence of Generalist Medical AI (GMAI) and Quantum Oncology (QO). Although GMAI's use foundation models, have high computational requirements and have inherent complexity in their validation pipelines, they are designed to be based on self-supervised learning from multimodal data to address a range of downstream clinical tasks. This review aims to critically discuss the potential of quantum computing (QC) to augment GMAI for more efficient data processing, medical imaging, drug discovery, and genomic analysis, owing to the inherent strengths of quantum superposition and entanglement that surpass the capabilities of classical AI/DL systems. Structural and technical trade-offs of this paradigm change are also discussed. We also give recommendations for safe bedside translation by facilitating a common assessment through clinician in the loop design, the CLAIM checklist, and the framework FUTURE-AI. Finally, this analysis outlines oncology and quantum convergence into quantum oncology (QO). This enables scalable, sustainable, and precision oncology while respecting ethics and privacy.
Quantum machine learning (QML) has emerged as a promising approach for analyzing the complex, high-dimensional data encountered in oncology, yet research in this area remains fragmented. This systematic literature review synthesizes current applications of QML in cancer care. Following PRISMA guidelines, six databases were searched for peer-reviewed English-language studies published between 2020 and 2026. Of the 212 records identified, 49 studies met the inclusion criteria after screening and quality assessment. The findings show that QML research is dominated by classification and detection tasks, while segmentation is beginning to emerge. Breast cancer and brain tumors are the most frequently investigated domains. Hybrid quantum-classical models, particularly quantum kernel methods, quantum neural networks, and quantum convolutional neural networks, are the predominant approaches. The main barriers to adoption are hardware limitations, including quantum noise, limited qubit availability, and reliance on simulators. Overall, QML in oncology remains in its early stages of development, with limited clinical validation, insufficient model interpretability, and little evidence of a clear quantum advantage. Future research should prioritize evaluation on real quantum hardware, larger and more diverse clinical datasets, standardized benchmarking against classical methods, and closer collaboration between computer scientists and oncology experts to facilitate clinical translation.